Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Cancer Services Delivery: Focus on India

Diagnostic performance and survival outcome of SLNB procedure in breast cancer patients from a tertiary cancer care centre

War in Ukraine: Impacts on the Ukrainian cancer care system

Recurrent non-invasive breast tumours may not always be related to the primary lesion

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations

Preventive oncology nutrition for healthy carriers and BRCA1/2 + breast cancer patients

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Eye metastasis in breast cancer: Case report and review of literature

Update on the new EUSOMA quality indicators for breast cancer